Clinical Trials Logo

Hemorrhagic Cystitis clinical trials

View clinical trials related to Hemorrhagic Cystitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT06241274 Not yet recruiting - Clinical trials for Hematopoietic Stem Cell Transplantation

Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT

Start date: January 25, 2024
Phase: N/A
Study type: Interventional

This study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation Patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation were given symptomatic supportive treatment combined with moxibustion covering Shenque, Zhongguo, Guanyuan, and Qihai for 30 minutes every day for 14 days and urine routine was collected every day for 14 days to assess the severity of hemorrhagic cystitis and pain scores to evaluate the effectiveness of moxibustion in treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

NCT ID: NCT06198517 Not yet recruiting - Clinical trials for Hematopoietic Stem Cell Transplantation

Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 254 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine was collected daily before cyclophosphamide administration until +14d, and blood/urine BK virus, JC virus, and adenovirus were tested at four time points: +1d, +14 days, appearance of hematuria symptom, and remission of HC, and urine routine was tested once every 7 days for all patients within three months, and severity grading should be performed for patients with Hemorrhagic cystitis (HC), pain scores, and the main TCM evidence profile, aiming to evaluate the effectiveness of moxibustion in preventing HC in this group of patients.

NCT ID: NCT05726786 Recruiting - Bladder Cancer Clinical Trials

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

INCyst
Start date: April 10, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy. As a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN. This is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.

NCT ID: NCT05348239 Recruiting - Clinical trials for Hemorrhagic Cystitis

Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs

CLARITY
Start date: March 26, 2022
Phase: Phase 2
Study type: Interventional

To assess the efficacy of oral chlorophyllin tablets for urinary bleeding following radiation therapy for cancers of pelvic organs.

NCT ID: NCT04696666 Recruiting - Clinical trials for Hemorrhagic Cystitis

Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis

Start date: May 15, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy and tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) in Patients with early or late symptoms of moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy. The study is conducted in the field of routine clinical practice and will recruit 30 subjects treated with intravesical instillations with INSTYLAN weekly for 6 weeks.

NCT ID: NCT04390113 Terminated - BK Virus Infection Clinical Trials

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Start date: March 18, 2021
Phase: Phase 3
Study type: Interventional

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).

NCT ID: NCT03129126 Completed - Clinical trials for Hemorrhagic Cystitis

The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus). Twelve subjects meeting the inclusion and exclusion criteria will be enrolled and treated in a prospective and multi-center trial with LP-10. The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.

NCT ID: NCT02174536 Recruiting - Clinical trials for Stem Cell Transplantation

A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

Start date: March 2014
Phase: Phase 2
Study type: Interventional

A prospective double blind randomized study comparing placenta derived decidual stromal cells with placebo for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy will be superior to placebo.

NCT ID: NCT02172963 Completed - Clinical trials for Hemorrhagic Cystitis

A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

Start date: November 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.